Key facts
- It has raised $340K; the latest was Early Stage VC in Dec 2025.
- Notable investors include Venture Kick, Kickfund, Gebert Rüf Foundation.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Caldre
- ·The full record, as it builds
Funding rounds
No funding rounds for Caldre are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Caldre
Developer of RNA-based therapeutics designed to treat cholestatic and fibrotic liver diseases and restore bile flow. The company offers liver-targeted GalNAc-siRNA technology focused on claudin-3 inhibition and modulation of bile composition, enabling patients with liver diseases to reduce tissue damage and delay the need for transplantation.
- Sector
- Healthcare
- HQ
- Bern, Switzerland
- Website
- caldre.ch/
- Ownership
- Privately Held (backing)
Caldre doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Caldre shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Caldre in its N-PORT filings yet. We sweep new filings monthly.